Candel Therapeutics, Inc.CADLNASDAQ

|||

Overview Charts News Fundamentals Key Metrics TTM Financials Earnings Growth Rating Analysts Institutional Peers Historical

Analyst Sentiment

Analysts lean bullish — 89% recommend buying.

Consensus Rating

Buy

9 analysts·Limited coverage

89%

Rating Distribution

Strong Buy

00%

Buy

889%

Hold

111%

Sell

00%

Strong Sell

00%

Analyst ratings reflect Wall Street opinion, not guarantees. Historical accuracy varies by firm and sector.

Price Target Expectations

Analysts see significant upside — consensus target 153% higher.

Bear Case

$15.00

+153%

Consensus

$15.00

+153%

Bull Case

$15.00

+153%

Price Range9 analysts

Low

Consensus

High

$15.00

Current Target

Current Price

$5.94

Upside to Target

$9.06

Price targets are 12-month forecasts. Actual results depend on earnings, market conditions, and sector trends.

Earnings & Revenue Estimates

2026E$-1.06(3 analysts)

Actual

Estimate

Range (Low–High)

Stock Alarm Pro

Forward Growth Estimates (YoY)

FY2027

Rev-37.30%

EPS—

FY2028

Rev+281.98%

EPS—

FY2029

Rev+114.95%

EPS+125.97%

Earnings Surprises

Beat rate:50%(6/12 quarters)

Avg surprise:+6.9%

Beat

Miss

Inline

Estimate

Based on reported EPS vs consensus estimate.

Recent Analyst Actions

Oct 27, 2025Stephens

Candel Therapeutics initiated with an Overweight at Stephens

Target:$15.00

+177.8%from $5.40

Explore More

S&P 500 Screener

Filter and sort all 500 stocks

Market Movers

Today's biggest gainers and losers

Market Heatmap

Visual sector performance